RE:RE:RE:Tilray Brands - GermanyGermany: Fact and Fiction Cannabis Sector Equity Research 26 February 2024 Pablo Zuanic ZUANIC & ASSOCIATES pablo.zuanic@zuanicgroup.com 420Odysseus;
www.zuanicassociates.com
https://zuanic.worldflowconnect.net/open/0176c2c4-ad2a-43a8-ae32-d90a3df0d0cf/240226%20Germany.pdf/07a73660-9328-46e2-9df8-6a8c563abaf9 Few remarks:
"While Friday was good for global cannabis, we are baffled by the way some stocks reacted on Friday to the news the Bundestag had approved “phase 1” (will not delve into the details). But therein lies the opportunity for shrewd long-term investors." "According to the summary, it appears Tilray is responsible for 35% of international sales to Germany and has one of the largest shares of the German medical cannabis industry (when compared to other listed stocks), and its footprint should grow considerably with increased demand and lessened restrictions."
"They are projecting TLRY for 900M (1.21B CDN) in revenue for 2024 and 100M in EBITDA (133M CDN). On a 40x multiple like some others in the cannabis industry are getting, that would be 4B market cap and selling price of 5.30$. Jeffries and their analyst (Owen Bennett) also reiterated similar findings and had a price target of 4.30$. Only a matter of time now, TLRY investors will be vindicated.
EBITDA of 160M for 2025 is even more bullish, let's go. With a 40x multiple, that's a stock price of 8.5$." NOTE: This Report missed the November reviews included in Friday’s vote.
Demecan lobbied to have Govt quotas on 'In Country' licensed producers removed, strains relaxed and distribution.
Made in Germany to reduce Foreign Imports.
Demecan, Aurora & Tilray big improvement. Advantage.